Verrica Pharmaceuticals Inc (NASDAQ: VRCA) established initial surge of 7.87% at $0.65, as the Stock market unbolted on Wednesday, before settling in for the price of $0.6 at the close. Taking a more long-term approach, VRCA posted a 52-week range of $0.38-$8.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been -5.46% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -5.46%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 77.72%. This publicly-traded company’s shares outstanding now amounts to $91.79 million, simultaneously with a float of $50.08 million. The organization now has a market capitalization sitting at $59.97 million. At the time of writing, stock’s 50-day Moving Average stood at $0.5540, while the 200-day Moving Average is $0.8248.
Verrica Pharmaceuticals Inc (VRCA) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Verrica Pharmaceuticals Inc industry. Verrica Pharmaceuticals Inc’s current insider ownership accounts for 45.85%, in contrast to 31.92% institutional ownership. According to the most recent insider trade that took place on Mar 17 ’25, this organization’s CHIEF LEGAL OFFICER sold 4,315 shares at the rate of 0.65, making the entire transaction reach 2,805 in total value, affecting insider ownership by 176,458. Preceding that transaction, on Aug 26 ’24, Company’s CHIEF LEGAL OFFICER sold 26,183 for 2.66, making the whole transaction’s value amount to 69,647. This particular insider is now the holder of 115,303 in total.
Verrica Pharmaceuticals Inc (VRCA) Earnings and Revenue Records
Verrica Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 77.72% and is forecasted to reach -0.22 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 76.18% through the next 5 years, which can be compared against the -5.46% growth it accomplished over the previous five years trading on the market.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
Let’s observe the current performance indicators for Verrica Pharmaceuticals Inc (VRCA). It’s Quick Ratio in the last reported quarter now stands at 1.26. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.35.
In the same vein, VRCA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.20, a figure that is expected to reach -0.08 in the next quarter, and analysts are predicting that it will be -0.22 at the market close of one year from today.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Now, what If we examine the latest scores posted by [Verrica Pharmaceuticals Inc, VRCA]. During the last 5-days, its volume was better the volume of 0.4 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 46.26% While, its Average True Range was 0.0668.
Raw Stochastic average of Verrica Pharmaceuticals Inc (VRCA) in the period of the previous 100 days is set at 66.96%, which indicates a major fall in contrast to 68.02% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 105.12% that was lower than 117.44% volatility it exhibited in the past 100-days period.
